Cardiorenal Risk Stratification Pilot Study (CRiSPS)
Cardiorenal Risk Stratification Pilot Study (CRiSPS): Using FGF-23 as a Risk Stratification Biomarker in Patients With Heart Failure and Chronic Kidney Disease as a Predictor of 1-year Morbidity and Mortality Risk
Sponsor: Coney Island Hospital, Brooklyn, NY
This observational or N/A phase trial investigates Cardio-Renal Syndrome and Chronic Kidney Diseases and is currently ongoing. Coney Island Hospital, Brooklyn, NY leads this study, which shows 7 recorded versions since 2018 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Nov 2018 — Nov 2020 [monthly]
Recruiting
-
Sep 2018 — Nov 2018 [monthly]
Recruiting
First recorded
Jul 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Coney Island Hospital, Brooklyn, NY
For direct contact, visit the study record on ClinicalTrials.gov .